Biogen acquires Nightstar Therapeutics

Biogen has completed the acquisition of the clinical-stage gene therapy company Nightstar Therapeutics, according to a press release.

The acquisition adds two mid- to late-stage clinical products — NSR-REP1 for the treatment of choroideremia and NSR-RPGR for the treatment of X-linked retinitis pigmentosa — and preclinical programs to Biogen’s portfolio.

“The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities,” Biogen CEO Michel Vounatsos said in the release. “We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

The transaction is valued at approximately $800 million.

Biogen has completed the acquisition of the clinical-stage gene therapy company Nightstar Therapeutics, according to a press release.

The acquisition adds two mid- to late-stage clinical products — NSR-REP1 for the treatment of choroideremia and NSR-RPGR for the treatment of X-linked retinitis pigmentosa — and preclinical programs to Biogen’s portfolio.

“The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities,” Biogen CEO Michel Vounatsos said in the release. “We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

The transaction is valued at approximately $800 million.